Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
Year: 2025
Type: article
Language: en
Topic: Gastric Cancer Management and Outcomes
Authors and affiliations:
raw_author_name: Keun-Wook Lee
raw_affiliation_strings: 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Seoul National University Bundang Hospital, Seongnam, Gyeongi, Korea (South), Republic of
raw_author_name: Li-Yuan Bai
raw_affiliation_strings: 2Division of Hematology and Oncology, China Medical University Hospital and China Medical University, Taichung, Taiwan
China Medical University Hospital, Taichung, Taiwan
raw_author_name: Minkyu Jung
raw_affiliation_strings: 3Division of Medical Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea
Yonsei University Health System, Seoul, Korea (South), Republic of
raw_author_name: Jieer Ying
raw_affiliation_strings: 4Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China
Zhejiang Cancer Hospital, Hangzhou, China
raw_author_name: Young-Hyuck Im
raw_affiliation_strings: 5Department of Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (South), Republic of
raw_author_name: Do-Youn Oh
raw_affiliation_strings: 6Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea
Seoul National University College of Medicine, Seoul, Korea (South), Republic of
raw_author_name: Jae Yong Cho
raw_affiliation_strings: 7Department of Oncology, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
Gangnam Severance Hospital, Seoul, Korea (South), Republic of
raw_author_name: Sang Cheul Oh
raw_affiliation_strings: 8Department of Oncology, Korea University Guro Hospital, Seoul, Republic of Korea
Korea University Guro Hospital, Seoul, Korea, Korea (South), Republic of
raw_author_name: Yee Chao
raw_affiliation_strings: 9Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan
raw_author_name: Jin Won Kim
raw_affiliation_strings: 1Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Seoul National University Bundang Hospital, Seongnam, Korea (South), Republic of
raw_author_name: Ye Chen
raw_affiliation_strings: 10Clinical Development, BeOne Medicines Ltd. (Beijing) Co., Ltd., Beijing, China
BeOne Medicines Ltd. (Beijing), Beijing, China
raw_author_name: Vincent Li
raw_affiliation_strings: 10Clinical Development, BeOne Medicines Ltd. (Beijing) Co., Ltd., Beijing, China
BeOne Medicines Ltd. (Beijing), Beijing, China
raw_author_name: Shengnan Chen
raw_affiliation_strings: 11Global Statistics and Data Science, BeOne Medicines Ltd. (Shanghai) Co., Ltd., Shanghai, China
BeOne Medicines Ltd. (Shanghai), Shanghai, China
raw_author_name: Yoon-Koo Kang
raw_affiliation_strings: 12Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea
Asan Medical Center, Seoul, Korea (South), Republic of